Loading
A phase 3 trial of Teclistamab, Pomalidomide, Bortezomib in multiple myeloma, run by Janssen Research & Development, LLC, active and no longer recruiting.
A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma is a phase 3 interventional study registered as NCT05572515 by Janssen Research & Development, LLC, with 614 participants enrolled, started 2023-03-29 and due to reach its primary completion in 2025-10-13. Interventions recorded: Teclistamab, Pomalidomide, Bortezomib, Dexamethasone, Carfilzomib. Conditions listed: Relapsed or Refractory Multiple Myeloma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Carfilzomib, Pomalidomide, Antiemetics for chemotherapy-induced nausea and vomiting, Bortezomib.
Shares Teclistamab, Pomalidomide, Antiemetics for chemotherapy-induced nausea and vomiting, Bortezomib.
Shares Pomalidomide, Antiemetics for chemotherapy-induced nausea and vomiting, Bortezomib, Dexamethasone.
Shares Pomalidomide, Antiemetics for chemotherapy-induced nausea and vomiting, Dexamethasone, Relapsed or refractory multiple myeloma.
Shares Pomalidomide, Antiemetics for chemotherapy-induced nausea and vomiting, Bortezomib, Dexamethasone.
Shares Carfilzomib, Pomalidomide, Antiemetics for chemotherapy-induced nausea and vomiting, Dexamethasone.
Shares Pomalidomide, Antiemetics for chemotherapy-induced nausea and vomiting, Dexamethasone, Relapsed or refractory multiple myeloma.
Shares Pomalidomide, Antiemetics for chemotherapy-induced nausea and vomiting, Dexamethasone, Relapsed or refractory multiple myeloma.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/